Neuro-immune modulations in Alzheimer's disease

Dear Colleagues,

Interactions between brain and the immune system has received immense interest over decades, and in the recent years the interest is greatly renewed due to the discovery of functional lymphatic vasculatures in the dura. Evidences show that besides resident immune cells of the CNS, the peripheral blood cells, such as dendritic cells and monocytes, constantly survey the CNS in steady state, contributing to a bidirectional communication between the CNS and the periphery. 
Cognitive deficit or dementia is the outcome of Alzheimer’s disease (AD), and to date is the most common form of dementia in the world. Inflammation is one of the prominent features of AD, the trigger of which is yet uncertain. Inflammation can contribute to the onset/progression of Alzheimer’s disease by activation of the innate immune response or by impaired adaptive immunity leading to chronic inflammation. On the other hand, protective anti-inflammatory cytokines, along with growth factors, have been shown to attenuate the disease progress in AD. Interestingly, deficits in peripheral immunity is also observed in subjects with AD. For example, myeloid dendritic cells were shown to be reduced, associated with severity in disease progression and depressive symptoms. In addition, several blood-derived metabolic and protein biomarkers are also emerging as crucial players in the diagnosis and prognosis of the disease. Therefore, a broader picture on the inter-communication between immunity and the CNS in Alzheimer’s disease is emerging. 
In this special issue, we invite submission of original research articles (in-vitro, animal and human studies), review articles, and perspectives that could stimulate the continuing efforts to better understand the relationship between immunity and Alzheimer’s disease. We welcome submissions from a broad range of topic, including (but not limited to): CNS and peripheral immune crosstalk, mechanism of action, immune modulatory factors, pathogenesis, biomarkers, experimental therapeutics, gut-brain axis, and disease models of AD. Articles focusing on other tauopathies are also welcome.

Dr. Santosh Jadhav

Guest Editor

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.